DENINTA 60MG INJECTION

Deninta 60mg Injection is made up of its active ingredient, Denosumab. It is a drug for treating osteoporosis characterized by weak bones. It can also be prescribed to reduce the risk of bone-related complications for patients suffering from certain kinds of cancer, including bone metastases and myeloma. Deninta 60 mg injection works by blocking a protein known as RANK, the ligand that is involved in the degrading of bone tissues. Research has demonstrated that it can significantly increase bone density while also reducing the risk of fracture for postmenopausal women who have osteoporosis, as well as patients suffering from osteoporosis-related loss of bones. Monitoring renal function closely is recommended for patients with moderate renal function impairment.
Deninta 60mg Injection is not to be used by patients suffering from known allergies or hypersensitivity in response to the components. Proper calcium and vitamin D supplement intake is essential to maintain the treatment. It is not a product that has been approved to be used in children or adolescents. Its efficacy and safety in children have not been proven. Therefore, its use is not recommended for those under 18 years old. This medication should be taken carefully in patients with pre-existing hypoparathyroidism, which is defined by low levels of parathyroid hormone.